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Summary 
Bacterial lipopolysaccharide (LPS) has been reported to induce immunoglobulin (Ig)G2b class 
switching, yet we observed strain differences in IgG2b secretion in response to this mitogen. 
Specifically, BALB/c B cells, unlike those from DBA/2, synthesized relatively low amounts of 
IgG2b relative to IgG3, IgG1, or IgM. This report demonstrates that transforming growth factor 
(TGF)31, previously shown to induce IgA dass switching, selectively stimulates IgG2b secretion 
by BALB/c resting B cells activated with LPS. This activity was specifically reversed with a 
neutralizing anti-TGF-31 antibody.  The ability  of TGF-3~ to  act directly on highly purified 
membrane (m)IgM+mlgG2b -  cells to stimulate  IgG2b production, stimulate  an increase in 
IgG2b-secreting cells, and selectively  increase the steady-state  levels of germline "/2b RNA, suggests 
that it promotes IgG2b class switching. In this regard, addition of anti-TGF-3 antibody to cultures 
of DBA/2-derived resting B cells activated by LPS, alone, led to selective reduction in IgG2b 
secretion, indicating that endogenous TGF-31 accounts for the high IgG2b secretory response 
observed in that strain. Finally, TGF-3~ failed to stimulate IgG2b secretion by B cells activated 
with dextran-conjugated anti-IgD antibody. We propose that TGF-31 is a switch factor for the 
murine IgG2b subclass for appropriately activated B cells. In combination with other data, this 
would show that all six non-IgM, non-IgD isotypes in the mouse can be selectively induced 
by specific cytokines. 
T 
GF-3,  is a pleiotropic  cytokine whose primary func- 
tions include stimulation of wound healing (1) and sup- 
pression of multiple immune cell types (2-4). TGF-31 can 
be released by a number of cell types including B cells, T 
cells, macrophages, and platelets (1-3, 5-8). TGF-~x was re- 
cently shown to stimulate IgA production by LPS-activated 
murine B cells in vitro by inducing an IgA class switch (9-13). 
Similar results were recently obtained using human B cells 
(14-16). 
LPS stimulates  large amounts of IgM and induces class 
switching to IgG3 and IgG2b (17, 18). We observed that 
the ratio of secreted IgG2b to that of IgG3, IgG1, or IgM 
upon LPS activation varied dramatically depending upon the 
strain of mouse from which the B cells were derived. Thus, 
B cells derived from BALB/c mice secreted relatively low 
amounts of IgG2b,  upon LPS stimulation, relative to cells 
obtained from DBA/2 mice. Since no cytokine has been de- 
scribed which regulates IgG2b secretion in a positive manner, 
we used LPS-activated B cells from BALB/c mice to screen 
for cytokines that selectively stimulate the expression of this 
Ig isotype.  We now show that TGF-31 selectively induces 
IgG2b secretion by LPS-, but not anti-IgD-dextran-, acti- 
vated B cells. This data supports our previous contention that 
the nature of the B cell activator plays a pivotal role in deter- 
mining cytokine-directed Ig isotype production (19, 20) and 
further indicates, in combination with other data, that three 
cytokines can selectively regulate two of the six non-IgM, 
non-IgD murine Ig isotypes in a positive manner: II:4:IgG1 
(21) and IgE (22); IFN-y: IgG2a (23) and IgG3 (20); and 
TGF-31: IgG2b  and IgA (9,  10). 
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Mice.  Female  BALB/c and DBA/2 mice were obtained from 
the National  Cancer Institute  (Frederick, MD) and were used at 
7-9 wk of age. 
Medium.  RPMI 1640 (Biofluids, Inc.,  Rockville, MD) sup- 
plemented with 10% fetal bovine serum (GIBCO BILL, Gaithers- 
burg, MD), t-glutamine  (2 mM), 2-ME (0.05 mM), penicillin (50 
/~g/ml), and streptomycin (50/,g/ml) were used for culturing cells. 
Preparation and Culture of B Cells.  Enriched, T-depleted popu- 
lations of small splenic B cells were obtained as described (24). Func- 
tional assays were carried out in 96-well flat-bottomed plates (Costar 
Corp.,  Cambridge, MA). Cultured cells were incubated at 37~ 
in a humidified atmosphere containing  6% CO2. 
Reagents.  LPS W, extracted from Escherichia coli 0111:B4, was 
obtained from Difco Laboratories, Inc. (Detroit, MI). Purified por- 
cine  and  bovine  natural  TGF-fll  were  obtained  from  g  &  D 
Systems, Inc. (Minneapolis, MN) and Cdtrix Pharmaceuticals (Santa 
Clara, CA), respectively.  Dextran-conjugated monodonal anti-IgD 
(H~ffl) (r  1 was prepared as previously described (25). rib5 
was prepared in the baculovirus system and was a kind gift from 
Dr. Richard Hodes (National Institutes of Health, Bethesda, MD). 
PE-labeled polyclonal goat anti-mouse IgM was obtained  from 
Southern Biotechnology Associates  (Birmingham, AL). Monoclonal 
rat IgG1 anti-mouse IgG2b was obtained from Pharmingen  (San 
Diego,  CA).  Monoclonal  mouse  IgG1  anti-TGF-fl (11311.16.8) 
(26) and a control mAb, mouse IgG1 anti-mouse IgMb-allotype 
(MB86) (27) were purified from ascites. B cells from BALB/c and 
DBA/2 mice express IgH of the a-allotype and hence do not bind 
MB86 (27). 
Electronic Cell  Sorting.  Highly  purified  (>99%)  membrane 
(m)IgM§  - B cells were obtained by electronic cell sorting 
of B calls stained with PE-anti-IgM plus FITC-anti-IgG2b  using 
a FACStar Plus  |  (Becton Dickinson & Co., Mountain View, CA) 
as described (28). 
Quantitation ofSecretedlg Isotypex  Ig isotype concentrations were 
measured by an ELISA assay as described (24). Briefly, Immulon 
2, %-well flat-bottomed ELISA phtes (Dynatech Laboratories, Inc., 
Alexandria, VA) were used, and a fluorescent product was gener- 
ated by cleavage of 4-methyl umbilliferyl phosphate  (Sigma Im- 
munochemicals, St. Louis, MO) with specifically bound alkaline 
phosphatase-conjugated antibodies. Ig isotype concentrations were 
determined by extrapolation  from standard curves. 
Quantitation of  lg Isotype-secreting Cells.  Ig isotype-secreting cells 
were quantitated by an ELISPOT assay (29). Briefly, flat-bottomed 
Immulon  I microtiter  plates (Dynatech Laboratories, Inc.), were 
coated with goat anti-mouse Ig and blocked with 1% BSA in PBS. 
Serial dilutions of single cell suspensions, starting  with 2  x  105 
cells/well, were incubated on anti-Ig-coated  plates for 7 h at 37~ 
in a 5% COs in air incubator. The cells were washed away with 
PBS/0.05%  Tween 20, and the plates were overlaid for 2 h with 
phosphatase-conjugated  isotype-specific antibodies  to mouse  Ig 
(Southern Biotechnology Associates). The antibodies produced by 
individual B cells which bound to the plate were visualized by ad- 
dition of a 5-bromo-3-chloroindolyl phosphate solution (Sigma Im- 
munochemicals). 
Detection of Steady-state Levels of Germline  C.9/3  and  C.T2b 
RNA.  Steady-state levels of germline C.~/3 RNA were measured 
by Northern blot analysis. 20/xg of total RNA, extracted from 
cultured cells, was separated, by dectrophoresis, in a formaldehyde- 
containing  1% agarose gel and blotted onto a nylon membrane 
1 Abbreviations used in this  paper: et~-dex, dextran-conjugated  anti-lgD anti- 
bodies; m, membrane. 
according to standard protocols. The blot was then hybridized with 
a eDNA specific for I3'3 (30) that was labeled with 32p-deoxy- 
cytidine by the random hexamer method, and was subsequently 
exposed to X-ray film. In addition, 20 #g of total RNA, extracted 
from the same cell populations that were utilized to measure germ- 
line "y3 transcripts, was hybridized to a 32p-labeled probe specific 
for germline  3~2b transcripts  to assay for  steady-state levels of 
germline C.3,2b RNA by the $1 nuclease protection  assay as de- 
scribed (31). 
Results and Discussion 
In initial experiments we observed that the relative amounts 
of IgG2b, IgG3, IgG1, and IgM secreted in response to LPS 
stimulation in vitro differed between B cells from BALB/c 
vs. DBA/2 mice. In four experiments BALB/c-derived B cells 
secreted 6-10-fold less IgG2b than DBA/2-derived B cells, 
whereas their  secretion of IgG3,  IgG1,  or IgM was either 
comparable  or  somewhat  higher  (Table  1).  Thus,  BALB/ 
c-derived B cells were used to search for cytokines which selec- 
tively stimulated IgG2b secretion in response to LPS. 
We observed that  purified bovine TGF-fll  stimulated  a 
dose-dependent increase in IgG2b and IgA secretion by LPS- 
activated B cells in vitro (Fig.  1). Maximal IgG2b and IgA 
secretion typically occurred between 0.3-1.0 ng/ml,  a dose 
range similar to that reported by others for maximal IgA en- 
hancement (9, 10). Optimal stimulation of IgG2b was ob- 
served when TGF-fll was added 24 h after addition of LPS 
and when cells were cultured at relatively high cell densities 
(2.5-10  x  10S/ml).  The TGF-fll-induced enhancement  in 
IgG2b secretion was observed in six separate experiments. 
In contrast, similar concentrations of TGF-B1 failed to stim- 
ulate, and variably inhibited,  LPS-induced IgM, IgG3, and 
IgG1 production (Fig.  1). Addition of TGF-B1 >1.0 ng/ml 
typically led to a decrease in all Ig isotypes, and this was as- 
sociated with a marked reduction in viable cell yields relative 
to that observed with LPS activation alone. This was consis- 
tent with the antiproliferative effect of TGF-fll described by 
others (2, 3). Similar results were obtained using purified por- 
cine  TGF-fll  (data  not  shown).  Although  it  has  been 
reported that  the addition of either  I1-5 or II.-2 can selec- 
tively enhance TGF-fll-mediated induction of IgA secretion 
by LPS-activated B cells (10),  we observed no selective in- 
duction of IgG2b secretion by either I1.-2 or Ib5 on LPS plus 
TGF-fll-activated cells  (data not  shown). 
Addition of increasing amounts of a neutralizing  mono- 
clonal  anti-TGF-fll  antibody  to  B  cell cultures  stimulated 
with LPS and  1.0 ng/ml  of TGF-fll resulted in a selective 
reduction in IgG2b secretion,  whereas an isotype-matched 
control mAb had no significant effect (Table 2). This indicated 
that the IgG2b-enhancing  activity was due to TGF-fl~  and 
not  some contaminant  in the TGF-fl~  preparation. 
To determine whether the TGF-fll-mediated increase in 
IgG2b secretion was due to an increase in the number  of 
IgG2b-secreting cells, or the amount of IgG2b secreted per 
cell,  the number of Ig isotype-secreting cells  generated in 
response  to  LPS  and  TGF-fll  was  determined  using  an 
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Ig secretion  Ratio 
Strain  IgG2b  IgG3  IgG1  IgM  3'3/3'2b  71/3'2b  /t/3,2b 
ng/ml 
BALB/c  85  5,000  310  52,500  59  3.6  620 
DBA/2  850  1,750  24  125,000  2.1  0.03  147 
B cells from each strain were cultured at 10S/ml in the presence of LPS for 4 d. Cells were then washed three times in medium to remove mAbs 
(murine IgG1), which would otherwise be measured in the IgGl-specific ELISA, and resupended in medium for an additional 2 d to allow for Ig 
secretion to occur. Culture supernatants were then removed for measurement of Ig isotype concentrations by ELISA. This data is representative 
of four similar experiments. 
ELISPOT assay (Fig. 2). Cells were analyzed 4.5 d after initi- 
ation of culture.  When expressed as the percentage of total 
Ig-secreting  cells  at  a  given  concentration  of TGF-fll,  a 
dose-dependent increase (maximal:  30-fold at  1.0 ng/ml of 
TGF-fl0 was observed for IgG2b-secreting cells.  By contrast 
the percentage of calls secreting IgM, IgG3, or IgG1 either 
remained stable or decreased.  1.0 ng/ml of TGF-fll induced 
a 5.4-fold increase in the absolute number of IgG2b-secreting 
cells relative to that observed with LPS alone. By contrast, 
the absolute numbers ofceUs secreting IgM, IgG3, and IgG1 
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Figure  1.  TGF-fll selectively  stimulates IgG2b 
and  IgA  secretion by  LPS-activated B  cells. 
BALB/c-derived  B cells were cultured for 24 h with 
LPS (40/zg/ml) at 5 x  10  s cells/ml in a total of 
100/zl of medium upon which varying concen- 
trations  of TGF-fll were added in  100  #1  of 
medium to achieve the final concentrations illus- 
trated in the figure. Culture supernatants were re- 
moved 6 d after initiation of culture and Ig iso- 
type concentrations  were measured by an ELISA. 
All groups were established in triplicate. 
Table  2.  Anti-TGF-fl mAb Specifically and Selectively Inhibits IgG2b Secretion by B Cells Activated with LPS Plus TGF-fll 
Ig secretion 
IgG2b  IgM  IgG3 
LPS 
LPS plus TGF-fll 
LPS plus TGF-fll plus  anti-TGF-fl 
LPS plus  TGF-fl plus  control mAb 
ng/ml 
130  47,900  1,250 
1,260  28,900  2,810 
265  53,900  2,140 
1,650  29,400  3,500 
BALB/c-derived B cells were stimulated for 24 h at 5  x  10S/ml in the presence of LPS (40/~g/ml).  24 h later T.GF-fll (final concentration 1.0 
ng/ml) with or without anti-TGF-fl (10/zg/ml final concentration) or control mAb (MB86) (10/zg/ml final concentration) were added to culture 
in an equal volume. Culture supernatants were removed 6 d after initiation of culture for measurement of Ig isotype concentrations by ELISA. 
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fold, respectively. Further addition of 1.0 ng/ml of TGF-B1 
to LPS-activated cultures led to a reduction of 2.5-fold in viable 
cell yields. Thus, TGF-B1 increased IgG2b secretion by LPS- 
activated B cells primarily by increasing the number of cells 
secreting Ig of that isotype. 
To determine whether TGF-~/1 acted directly on B cells 
and  stimulated class switching,  highly  purified  (>99%) 
mlgM  +  mlgG2b- cells were isolated by electronic cell sort- 
ing and stimulated with LPS in the presence or absence of 
TGF-~I (Table 3). TGF-~/1 selectively induced IgG2b secre- 
tion by LPS-activated mlgM+mlgG2b -  cells indicating its 
direct action on the B cell and suggesting that it promoted 
a class switch to IgG2b. 
An increase in the steady state levels of germline C. RNA 
specific for  a  particular  C,  gene  typically  precedes  class 
switching to the expression of that gene (32, 33). To further 
assess whether TGF-~I acted as a switch factor for IgG2b 
we  determined  whether  it  selectively  induced  germline 
C.~/2b  RNA in LPS-activated B cells (Fig.  3). TGF-B1 in- 
duced a 2-2.5-fold increase in the steady-state levels of germ- 
line C,'y2b RNA in LPS-activated B cells while concomi- 
tantly reducing, by 2-2.5-fold, the levels of germline C.'y3. 
The enhancement in steady-state levels of germline C,3'2b 
RNA by TGF-~I was 2-3-fold lower than the associated in- 
duction of IgG2b secretion.  However,  steady-state levels of 
germline C.'y2b  RNA  may underestimate the  degree of 
transcriptional activation of the C.'y2b gene, the relation- 
ship between germline C. gene transcription and Ig class 
switching may not be a linear one, and/or other parameters 
in the response  of B cells to TGF-~I may further regulate 
IgG2b synthesis. 
Additional experiments demonstrated that a neutralizing 
anti-TGF-B1 antibody  specifically  and  selectively  reduced 
IgG2b secretion by LPS-activated DBA/2-derived B cells (Fig. 
4). Thus, it appears that endogenous TGF-~I accounted for 
the ability of DBA/2-derived B cells to synthesize relatively 
high amounts of IgG2b in response to LPS. 
We previously determined that cross-linkage of the antigen 
receptor of small B cells by dextran-linked anti-IgD (cz6-dex) 
provided a powerful costimulus for cytokine-directed Ig iso- 
type production (34). Yet, o~6-dex  was unable to costimulate 
an IgE response in the presence of even high concentrations 
of IL-4 (19). We further observed a distinct lack of IgG2b 
secretion  by  ol&dex-activated  B  cells  in  the  presence  of 
cytokines contained within either activated  CD4 § Thl or 
Th2 supernatants  (19). To determine whether TGF-B1 could 
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Figure 2.  TGF-B1  selectively  stimulates an increase in IgG2b-secreting 
cells  in the presence ofLPS. BALB/c-derived  B cells were cultured for 24 h 
with LPS (40/~g/ml) at 5  x  10  s cells/ml in a volume of 5 ml of medium 
upon which varying concentrations  of TGF-B1 were added in 5 ml of 
medium to achieve the final concentrations illustrated in the figure. Cells 
were harvested  4.5 d after initiation  of  culture for quantitation of Ig isotype- 
secreting cells by an ELISPOT assay. 
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Figure 3.  TGF-~I selectively  stimulates an increase  in steady-state  levels 
of germline C~3'2b RNA by LPS-activated  B cells. BALB/c-derived  B cells 
were cultured for 24 h in the presence of LPS (40 #g/m1) and either anti- 
TGF-B1 mAb  (11911.16.8) (10  #g/m1)  to  neutralize  any endogenous 
TGF-/31, or an isotype-matched control mAb (MB86) (10 #g/ml) at 5  x 
10S/ml in 25 ml of medium upon which medium alone or TGF-Bt (2.0 
ng/ml), respectively, were added in 25 ml of medium, Cells were har- 
vested 3 d after initiation  of culture and total KNA was extracted for quan- 
titation of steady-state levels of germline C.3"2b by the $1 nuclease pro- 
tection assay or C.3'3 by Northern blot analysis.  Ethidium bromide (EtBr) 
staining  of RNA is included to show essentially equal quantities of RNA 
used from each group. Table  3.  TCF-/9 Acts Directly on  mlgM+mlgG2b -  B  Cells  to Stimulate  IgC2b Secretion 
Ig secretion 
Nonsorted  mlgM*mlgG2b- 
IgM  IgG2b  IgG3  IgM  IgG2b  IgG3 
ng/ml 
LPS  119,000  86  1,800  175,000  290  2,150 
LPS +TGF-31  46,250  500  3,000  106,000  2,600  4,250 
Small splenic B cells were stained with FITC-anti-IgG2b plus PE-anti-IgM, mlgM+mlgG2b -  cells were isolated by electronic cell sorting to >99% 
purity and stimulated with LPS (40 #g/ml) at 5  x  10  s cells/ml.  24 h later, an equal volume of medium with or without 1.0 ng/ml of TGF-31 
was added. Culture supernatant was removed 6 d after initiation of culture with LPS, and IgM, IgG3, and IgG2b concentrations were measured by ELISA. 
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Figure  4.  Anti-TGF-B1  selectively inhibits 
IgG2b secretion by DBA/2-derived, LPS-activated 
B cells. DBA/2-derived, B cells were cultured at 
1.5  x  10  s cells/ml in LPS (20/~g/ml) in the pres- 
ence  or  absence of  either  anti-TGF-31 mAb 
(1Dl1.16.8) (1 #g/ml) or an isotype-matched con- 
trol mAb (MB86) (1 #g/ml), Culture supematants 
were harvested 6 d after initiation of culture for 
measurement  of Ig  isotype  concentrations  by 
ELISA. All groups were established in triplicate. 
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Figure  5.  TGF-B1  stimulates IgG2b secretion by LPS- 
stimulated, but not ot~-dex plus IL-S-activated  B cells. 
BALB/c-derived  B cells were cultured with LPS (40 #g/rnl) 
or oeS-dex (6 ng/ml) plus IL-5 (300 U/ml) for 24 h in 
100 #1 of medium upon which varying concentrations of 
TGF-31 were added in 100 #1 of medium for the final 
concentration illustrated in the figure. Culture superna- 
tants were removed 6 d after initiation of culture for mea- 
surement of IgM and IgG2b concentrations by ELISA. 
All groups were established in triplicate. 
induce IgG2b secretion by oe~-dex-activated B cells, we added 
varying amounts of TGF-31 to B cells induced  to secrete Ig 
by c~&dex plus IL-5 (Fig. 5). Although TGF-3, dearly acted 
on  c~r  plus  IL-5-activated cells by virtue  of its  ability 
to inhibit IgM secretion in a dose-dependent fashion, it failed 
to  stimulate  detectable  secretion  of  IgG2b.  This  further 
supported our model that the nature of the B cell activator 
plays a pivotal role in cytokine-directed  Ig isotype produc- 
tion  (19,  20). 
Thus,  our  data  strongly  suggests  that  TGF-flt  stimu- 
lates IgG2b class switching by LPS-activated B cells in that 
TGF-31: (a) selectively stimulates the secretion of only IgG2b 
1035  Mclntyre et al. and  IgA;  (b)  selectively increases  the  number  of IgG2b- 
secreting cells;  (c) acts  on mlgM+mlg2b -  cells to induce 
IgG2b secretion; and (d) increases  the steady-state levels of 
germline C,3,2b  RNA. 
In light of our findings, it is of interest that an earlier study 
demonstrating the ability of TGF-~l to selectively stimulate 
IgA production found that TGF-B1 inhibited the secretion 
of IgM, IgG3, IgG1, and IgG2a, but did not inhibit the syn- 
thesis of IgG2b (10). The failure to see a significant induc- 
tion in IgG2b secretion may have reflected, in part, the rela- 
tively high levels of IgG2b secretion induced by LPS alone, 
perhaps due to endogenous TGF-B1. In this regard, we ob- 
served that although DBA/2-derived B cells made substan- 
tial amounts of IgG2b in response to LPS alone (secondary 
to endogenous TGF-/81), they secreted only modest amounts 
of IgA (comparable with  that  seen utilizing B cells from 
BALB/c mice). This could in part reflect the need for some- 
what higher concentrations of TGF-B1 for optimal IgA vs. 
IgG2b secretion as is suggested in Fig.  1. 
Another group, which earlier reported the ability of  joint 
fluids from rheumatoid arthritis patients to selectively stimulate 
IgG2b-secreting murine B cells when cultured by LPS in vitro 
(35),  found no affect of TGF-~I on IgG2b induction (36). 
Although the reason for this is presently unclear, the failure 
of  human  TGF-~I  at  1  and  2  ng/ml,  to  diminish  the 
number of IgM-, IgGl-, and IgG3-secreting cells over that 
seen with LPS alone calls into question the activity of their 
TGF-31 preparation.  Nevertheless, the IgG2b-inducing ac- 
tivity in joint fluids was ascribed to a 50-60 kD molecule, 
suggesting that a factor in addition to TGF-B1 may also be 
capable of enhancing the secretion of IgG2b. 
We are currently investigating the basis for the strain-related 
differences in  magnitude of in  vitro  LPS-induced  IgG2b 
secretory responses.  Preliminary work from our laboratory 
suggests that LPS-activated DBA/2-derived B cells secrete 
TGF-/31. Whether the differences in IgG2b secretion among 
B cells derived from other strains of mice reflect differences 
in the amount of endogenous TGF-31 produced, or whether 
these B cells have differing sensitivities to TGF-31  action, 
needs to be determined. It is interesting that we recently 
observed that BALB/c mice immunized with LPS produced 
lower levels of serum, LPS-specific  IgG2b, relative to IgM 
and IgG3, when compared with similarly immunized DBA/2 
mice (Snapper, C. M., unpublished observations). Whether 
TGF-31 plays  a physiologic role in the in vivo IgG2b re- 
sponse to LPS immunization is being investigated. Finally, 
it will be interesting to determine whether the constitutive, 
selective expression of germline C,3'2b transcripts  and C.3'2b 
rearrangement typically seen in murine Abelson virus-trans- 
formed pre-B cell lines (33) is also due to endogenous produc- 
tion of TGF-3I. 
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